What is ALS?
Amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrigs disease, is a progressive neurodegenerative disorder that attacks the motor neurons in the brain and spinal cord. These neurons control voluntary muscle activity; when they die, the brain can no longer send signals to the muscles, leading to weakness, atrophy, and eventually loss of function.
ALS occurs worldwide, affecting roughly 23 people per 100,000 each year. Most cases appear between ages 55 and 75, though the disease can develop in younger adults and, rarely, in children. About 510% of ALS cases are inherited (familial ALS), while the majority are sporadic, with no clear family link.
Common Symptoms
Symptoms usually begin subtly and progress over months to years. The pattern varies from person to person, but the typical early signs include:
- Muscle weakness in a limb (hands, arms, legs) or in the tongue
- Frequent tripping or dropping objects
- Slurred or nasal speech
- Muscle cramps and twitching (fasciculations)
- Difficulty swallowing (dysphagia)
As the disease advances, patients may experience:
- Generalized muscle wasting and paralysis
- Respiratory failure caused by weakening of the diaphragm and intercostal muscles
- Emotional changes such as depression or anxiety
- Increased difficulty communicating, sometimes requiring eyetracking devices
Importantly, cognitive function remains largely intact for most people, although up to 50% develop some degree of frontotemporal dementia.
How ALS Is Diagnosed
There is no single test for ALS. Diagnosis relies on a combination of clinical examination, patient history, and exclusion of other conditions. Typical steps include:
- Neurological exam: doctors assess muscle strength, reflexes, coordination, and speech.
- Electromyography (EMG): measures electrical activity in muscles to confirm the loss of motor neuron input.
- Nerve conduction studies: help differentiate ALS from peripheral neuropathies.
- MRI or CT scans: used to rule out spinal cord compression, tumors, or multiple sclerosis.
- Blood and urine tests: rule out metabolic or infectious causes of weakness.
Because symptoms may overlap with other disorders, the diagnostic process can take several months. Early referral to a multidisciplinary ALS clinic improves accuracy and speeds up access to supportive care.
Treatment, Management, and Supportive Care
While no cure exists, several interventions can extend survival, improve quality of life, and alleviate symptoms.
Pharmacological options
- Riluzole: the first FDAapproved drug; modestly prolongs survival by reducing glutamate toxicity.
- Edaravone: an antioxidant shown to slow functional decline in a subset of patients.
- Symptomspecific medications (e.g., antispasmodics for muscle cramps, antidepressants for mood, sialagogues for dry mouth).
Respiratory support
Noninvasive ventilation (BiPAP) is introduced when forced vital capacity falls below 50% of predicted. As disease progresses, tracheostomy with invasive ventilation may be considered, always in line with the patients goals.
Nutrition
Difficulty swallowing often leads to weight loss and aspiration risk. Early placement of a feeding tube (PEG) helps maintain nutrition and reduces pneumonia incidence.
Physical and occupational therapy
Therapists design individualized exercise programs to preserve mobility, prevent contractures, and provide assistive devices such as braces, walkers, or wheelchairs.
Speech & communication
Speech-language pathologists work on strategies for articulation, augmentative communication (AAC) devices, and eyegaze systems for advanced stages.
Emotional & psychosocial support
Psychologists, social workers, and support groups are essential for patients and caregivers coping with the emotional burden of ALS.
Current Research Directions
Scientists are exploring disease mechanisms and novel therapies on several fronts:
- Genetic therapies: antisense oligonucleotides (ASOs) targeting SOD1, C9orf72, and other ALSlinked genes have shown promise in early trials.
- Stemcell transplantation: motor neuron progenitor cells are being investigated for neuroprotection.
- Neuroinflammation modulation: drugs that dampen microglial activation aim to slow disease progression.
- Biomarker discovery: blood and cerebrospinal fluid markers (e.g., neurofilament light chain) are improving early detection and trial recruitment.
Clinical trials are ongoing worldwide. Participation can be found through ALS Association trial registries or local ALS centers.
Helpful Resources
Below are reputable organizations that provide information, financial assistance, and community support.
- ALS Association (USA) education, research funding, and caregiver programs.
- Muscular Dystrophy Association ALS grants, equipment loans, and counseling.
- International ALS Community global network of patients, clinicians, and researchers.
- ClinicalTrials.gov searchable database of current ALS studies.
